LWM
ANIP icon

LBA Wealth Management’s ANI Pharmaceuticals ANIP Stock Holding History

LBA Wealth Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$6K Hold
125
– – ﹤0.01% 348
2016
Q4 		$8K Sell
125
-200
-62% -$12.2K ﹤0.01% 334
2016
Q3 		$22K Buy
+325
New +$20.3K 0.01% 253

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LBA Wealth Management's ANIP Position: Q1 2017 in Review

LBA Wealth Management held its ANI Pharmaceuticals (ANIP) position steady in Q1 2017 at 125 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #348.

LBA Wealth Management first reported a position in ANIP in Q3 2016 and has held it in 3 quarters since. The position peaked at $22K in Q3 2016. 158 funds tracked by Wall St. Rank hold ANIP as of Q1 2017.

  • LBA Wealth Management held 125 shares of ANI Pharmaceuticals worth $6K as of Q1 2017.
  • LBA Wealth Management left its ANI Pharmaceuticals share count unchanged in Q1 2017.
  • ANI Pharmaceuticals made up ﹤0.01% of LBA Wealth Management's portfolio in Q1 2017, its #348 holding.
  • LBA Wealth Management first reported a position in ANI Pharmaceuticals in Q3 2016 and has held it in 3 quarters since.
  • LBA Wealth Management's ANI Pharmaceuticals position peaked at $22K in Q3 2016.
  • 158 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2017.

Based on LBA Wealth Management's 13F filing for Q1 2017, filed 9 May 2017.